Business Description
Summit Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US86627R1023
Share Class Description:
SMMT: Ordinary SharesDescription
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.76 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.37 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -9.7 | |||||
| 3-Year EPS without NRI Growth Rate | 41.3 | |||||
| 3-Year FCF Growth Rate | 43.8 | |||||
| 3-Year Book Growth Rate | -51.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.83 | |||||
| 9-Day RSI | 54.68 | |||||
| 14-Day RSI | 53.22 | |||||
| 6-1 Month Momentum % | 92.5 | |||||
| 12-1 Month Momentum % | 154.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.3 | |||||
| Quick Ratio | 9.3 | |||||
| Cash Ratio | 9.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -104.1 | |||||
| Shareholder Yield % | 1.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -552.19 | |||||
| ROA % | -194.86 | |||||
| ROIC % | -640.65 | |||||
| ROC (Joel Greenblatt) % | -951.9 | |||||
| ROCE % | -217.54 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 36.91 | |||||
| Price-to-Tangible-Book | 36.91 | |||||
| EV-to-EBIT | -5.42 | |||||
| EV-to-EBITDA | -5.44 | |||||
| EV-to-FCF | -42.21 | |||||
| Price-to-Net-Current-Asset-Value | 45.11 | |||||
| Price-to-Net-Cash | 45.11 | |||||
| Earnings Yield (Greenblatt) % | -18.45 | |||||
| FCF Yield % | -2.7 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers